The financials
United Therapeutics Corporation by the numbers
United Therapeutics Corporation (UTHR) reported revenue of $782M in Q1 2026 (quarter ended Mar 31, 2026), down 1.6% from the same quarter a year earlier. That came with a gross margin of 83% and net income of $275M (35% of revenue). For the full year FY2025, revenue was $3.18B (+11% year on year) and net income $1.33B. Its largest product in Jun 2026 was Tyvaso DPI at $327M, 42% of the disclosed total, well ahead of Remodulin at 16%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $782M | $794M | −1.6% |
| Gross profit | $648M | $702M | −7.7% |
| Operating income | $326M | $383M | −15% |
| Net income | $275M | $322M | −15% |
| Diluted EPS | $5.82 | $6.63 | −12% |
| Product | Revenue | Share |
|---|---|---|
| Tyvaso DPI | $327M | 42% |
| Remodulin | $126M | 16% |
| Nebulized Tyvaso | $126M | 16% |
| Orenitram | $126M | 16% |
| Unituxin | $65M | 8.3% |
| Product And Service Other | $6.8M | 0.9% |
| Adcirca | $6.7M | 0.9% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $783.3M (+0.23%)
Product And Service Other grew +24% year on yearNebulized Tyvaso -18% year on year
Segment Latestquarter on quarteryear on year
- Tyvaso DPI$326.6M$326.6MQoQ -1.1%year on year +3.6%-1.1%+3.6%
- Remodulin$126.3M$126.3MQoQ -0.24%year on year -6.2%-0.24%-6.2%
- Nebulized Tyvaso$126.0M$126.0MQoQ -0.94%year on year -18%-0.94%-18%
- Orenitram$125.7M$125.7MQoQ -7.3%year on year +1.5%-7.3%+1.5%
- Unituxin$65.2M$65.2MQoQ +22%year on year +12%+22%+12%
- Product And Service Other$6.8M$6.8MQoQ +28%year on year +24%+28%+24%
- Adcirca$6.7M$6.7MQoQ +131%year on year +3.1%+131%+3.1%
Drug Manufacturers - Specialty & Generic
Ranks #9 of 29 by Smart Score